TG announces updated data presentations from ULTIMATE I, II Phase 3 trials

TG Therapeutics (TGTX) announced updated data presentations including new six-year data from the ULTIMATE I & II Phase 3 trials evaluating BRIUMV/i in patients with relapsing forms of multiple sclerosis, RMS, at the 2025 European Committee for Treatment and Research in Multiple Sclerosis, ECTRIMS, annual meeting. Bruce Cree, MD, PhD, MAS, Zimmermann Endowed Professor in Multiple Sclerosis, and Professor of Neurology at UCSF Weill Institute for Neurosciences, University of California, San Francisco stated, “The data for BRUIMVI at six years of continuous therapy provides compelling evidence of durable efficacy, with sustained protection against not only relapses but also disability progression. These data also underscore the benefit of early treatment with ublituximab compared to delayed treatment on disability outcomes. Furthermore, the consistency of outcomes in clinical trials compared with emerging data from observational studies is striking and strongly supports use of ublituximab in clinical practice.”